The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.
Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Value
|
85 | 99 | n/a | n/a |
Growth
|
35 | 27 | n/a | n/a |
Safety
|
18 | 19 | n/a | n/a |
Sentiment
|
92 | 94 | n/a | n/a |
|
65 | 85 | n/a | n/a |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Analyst Opinions
|
74 | 44 | n/a | n/a |
Opinions Change
|
93 | 83 | n/a | n/a |
Pro Holdings
|
n/a | 90 | n/a | n/a |
Market Pulse
|
77 | 87 | n/a | n/a |
Sentiment
|
92 | 94 | n/a | n/a |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Value
|
85 | 99 | n/a | n/a |
Growth
|
35 | 27 | n/a | n/a |
|
18 | 19 | n/a | n/a |
Combined
|
31 | 45 | n/a | n/a |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Price vs. Sales (P/S)
|
57 | 71 | n/a | n/a |
Price vs. Earnings (P/E)
|
60 | 59 | n/a | n/a |
Price vs. Book (P/B)
|
50 | 52 | n/a | n/a |
Dividend Yield
|
80 | 90 | n/a | n/a |
Value
|
85 | 99 | n/a | n/a |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Revenue Growth
|
20 | 21 | n/a | n/a |
Profit Growth
|
29 | 41 | n/a | n/a |
Capital Growth
|
70 | 33 | n/a | n/a |
Stock Returns
|
51 | 59 | n/a | n/a |
Growth
|
35 | 27 | n/a | n/a |
Metrics | Current | 2024 | 2023 | 2022 |
---|---|---|---|---|
Leverage
|
22 | 31 | n/a | n/a |
Refinancing
|
17 | 4 | n/a | n/a |
Liquidity
|
67 | 82 | n/a | n/a |
|
18 | 19 | n/a | n/a |
Discover high‑ranked alternatives to GE Healthcare and broaden your portfolio horizons.
The Obermatt Advantage
Choose the Obermatt subscription that best fits your needs.